(Reuters) - "It is possible that we do both, acquisitions and share buybacks ," Vasella said in an interview in newspaper Finanz und Wirtschaft.
MedImmune said this week it had hired bankers to explore a sale of the company, which could fetch up to $12 billion.
Read more at Reuters.com Mergers News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment